June 28 (Reuters) - Moderna Inc:
* EMA SAYS CHMP GRANTING A MARKETING AUTHORISATION FOR BALVERSA
* EMA: MRESVIA RSV MRNA VACCINE RECEIVED A POSITIVE OPINION FROM THE CHMP FOR PREVENTION IN ADULTS 60 YEARS OF AGE AND OLDER
* EMA: CHMP RECOMMENDED GRANTING MARKETING AUTHORISATION FOR WINREVAIR, TO TREAT ADULT PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION
* EMA SAYS CHMP GAVE POSITIVE OPINION TO UPDATE THE COMPOSITION OF MRNA VACCINE COMIRNATY TO TARGET NEW SARS-COV-2 JN.1 VARIANT OF VIRUS
* EMA: PIASKY RECEIVED A POSITIVE OPINION FROM CHMP FOR TREATMENT OF PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA
* EMA: CHMP RECOMMENDED GRANTING MARKETING AUTHORISATION FOR STEQEYMA TO TREAT MODERATELY-TO SEVERELY-ACTIVE CROHN’S DISEASE, PLAQUE PSORIASIS
* EMA: CHMP GAVE POSITIVE OPINION FOR TAUVID (FLORTAUCIPIR (18F)), FOR PET IMAGING OF THE BRAIN
* EMA: CHMP CONCLUDED ITS REVIEW OF OCALIVA AND RECOMMENDED THE MEDICINE’S CONDITIONAL MARKETING AUTHORISATION SHOULD BE REVOKED Source text for Eikon: Further company coverage: